Cell therapy lisocabtagene maraleucel will be approved in 2020

Wen Jie 1 degrees C On February 13, 2020, Bristol Myers Squibb announced that FDA accepted the listing application of LISO cel The indication of this application for listing is adult relapse / refractory large B-cell lymphoma FDA granted it the priority review qualification PDUFA is August 17, 2020 This is a memorable moment, lasting for nearly one year After Bristol Myers Squibb acquired celgene, car-t cell therapy products ushered in milestone progress Lisocabatagene maraleucel (jcar017) has attracted much attention due to its higher safety and better clinical benefits https:// Car-t cell therapy has brought revolutionary progress to the treatment of hematoma, especially B-cell hematoma We have known that car-t cell therapy can bring super high complete remission rate (> 30%) to B-cell hematoma such as DLBCL and all patients, and also create the miracle of Emily Whitehead's life; At the same time, car-t cell therapy also brings a high proportion of severe cytokine storm and neurotoxicity For example, kymriah of Novartis and yescarta of Gilead, the incidence of CRS at all levels is more than 50%, and neurotoxicity at all levels is more than 21% Kymriah-NCT02445248 Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma Yescarta- NCT02348216 Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma From the above, we can see that the advantages and disadvantages of car-t cell therapy are very obvious, so developing strengths and avoiding weaknesses is the key to win the future Lisocabtagene maraleucel: complete remission up to 53%, CRS and neurotoxicity data are gratifying At present, lisoabtargene maraleucel of Bristol Myers has done a good job Ash 2019 data display: Lisocabtargene maraleucel can bring deep remission to B-cell non Hodgkin's lymphoma patients Low CRS and neurotoxicity Transcend NHL 001 - nct02631044 is also the key clinical data to support the listing application of lisoabtagene maraleucel Based on its more excellent safety data, lisoabtagene maraleucel is expected to become the best in class, and will be the driving force for its future market development At present, lisoabtagene maraleucel is involved in a number of clinical trials, and the future development of the drug deserves attention.